Argireline

Skin & hair Supplement / supply Human trials

Also called Acetyl hexapeptide-8, Acetyl hexapeptide-3

A six-amino-acid cosmetic peptide modelled on the SNAP-25 protein that nerve endings use to release acetylcholine. The idea is to interfere with that release and soften expression lines — the same pathway botulinum toxin blocks, far more weakly and from outside the skin.

Evidence at a glance

Evidence
Human trials — Studied in people
Status
Supplement or supply
Dosing
No human study has set a dose

Most efficacy data comes from the companies selling it, and a peptide this size struggles to penetrate skin far enough to reach nerve endings. Effects, where present, are modest and nothing like an injectable.

What studies report

How it works

Competes with SNAP-25 in the SNARE complex, reducing the neurotransmitter release that drives muscle contraction.

Binds a receptor on the cell surface and signals inward

Where it acts

Acts in the skin, throughout the body

The library groups this compound under Skin & hair. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Expression lines and wrinklesTopical alternative to injectables

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Reported real-world use, not evidence and not a recommendation.

Status: Cosmetic ingredient. Not a medicine.

Route
Topical, in creams and serums
Formula
C35H62N14O11S
Molecular weight
887.0 g/mol
CAS
616204-22-9
Available as
Topical cream
View on PubChem →

Search PubMed for Argireline → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.